Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07323017
Active, not recruiting Observational

Electrochemotherapy in Musculoskeletal Tumors

NCT07323017 · tracked via the Priya Life Science Italy tracker
Sponsor
Costantino Errani
Phase
Observational
Started
2025-08-01
Last updated
2026-01-14

Condition(s) studied

Bone Tumors

Study summary

The study involves the enrollment of patients over 2 years of age with a diagnosis of musculoskeletal tumors and an indication for electrochemotherapy, treated at the Rizzoli Orthopaedic Institute in Bologna and followed during outpatient follow-up. Data will be collected from medical records, outpatient reports, and imaging studies including CT, X-ray, MRI, and/or PET.

For the retrospective part of the study, patients treated at the Rizzoli Orthopaedic Institute from 01/01/2024 to the date of approval of this study will be included. For the prospective part, patients meeting the inclusion criteria and treated from the study start date until 31/12/2030 will be enrolled.

Eligibility

Sex
ALL
Min age
2 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients of both sexes with a histological diagnosis of a primary musculoskeletal tumor, either benign or malignant, located outside the abdominal cavity (trunk and limbs) * Indication for electrochemotherapy due to one of the following conditions: 1. Clinical conditions contraindicating surgery 2. Tumor not surgically resectable * Patients treated with electrochemotherapy at the Rizzoli Orthopaedic Institute: 1. From 01/01/2024 to the date of study approval for the retrospective phase 2. From the date of study approval to 12/31/2030 for the prospective phase * Retrospectively treated patients with a minimum follow-up of at least 3 months * Age ≥ 2 years at the time of treatment * Availability of clinical and instrumental data Exclusion Criteria: • Failure to meet at least one of the inclusion criteria

Primary outcome measure(s)

  • Tumor size will be assessed using CT, MRI, X-ray, and/or PET imaging. Tumor size will be defined as the longest diameter of the target lesion (mm). — 3, 6, and 12 months after electrochemotherapy

Trial sites (1)

FacilityCityRegionStatus
Irccs Istituto Ortopedico Rizzoli Bologna Emilia-Romagna

More Costantino Errani trials in Italy

Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic Results Recruiting
Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma Recruiting
Analysis of Intramedullary Nail and Prosthetic Reconstruction After Surgical Treatment of Bone Metastases of Proximal Femur Recruiting
Pediatric Oncological Orthopaedic Reconstruction Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07323017 on ClinicalTrials.gov ↗ ← All trials in Italy